Literature DB >> 14662896

Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma.

Ekaterina S Doubrovina1, Mikhail M Doubrovin, Elena Vider, Richard B Sisson, Richard J O'Reilly, Bo Dupont, Yatin M Vyas.   

Abstract

Evasion of host immune responses is well documented for viruses and may also occur during tumor immunosurveillance. The mechanisms involve alterations in MHC class I expression, Ag processing and presentation, chemokine and cytokine production, and lymphocyte receptor expression. Epithelial tumors overexpress MHC class I chain-related (MIC) molecules, which are ligands for the activating receptor NKG2D on NK and T cells. We report that NK cells from patients with colorectal cancer lack expression of activating NKG2D and chemokine CXCR1 receptors, both of which are internalized. Serum levels of soluble MIC (sMIC) are elevated and are responsible for down-modulation of NKG2D and CXCR1. In contrast, high serum levels of CXC ligands, IL-8, and epithelial-neutrophil-activating peptide (ENA-78) do not down-modulate CXCR1. In vitro, internalization of NKG2D and CXCR1 occurs within 4 and 24 h, respectively, of incubating normal NK cells with sMIC-containing serum. Furthermore, natural cytotoxicity receptor NKp44 and chemokine receptor CCR7 are also down-modulated in IL-2-activated NK cells cocultured in MIC-containing serum-an effect secondary to the down-modulation of NKG2D and not directly caused by physical association with sMIC. The patients' NK cells up-regulate expression of NKG2D, NKp44, CXCR1, and CCR7 when cultured in normal serum or anti-MIC Ab-treated autologous serum. NKG2D(+) but not NKG2D(-) NK cells are tumoricidal in vitro, and in vivo they selectively traffic to the xenografted carcinoma, form immunological synapse with tumor cells, and significantly retard tumor growth in the SCID mice. These results suggest that circulating sMIC in the cancer patients deactivates NK immunity by down-modulating important activating and chemokine receptors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14662896     DOI: 10.4049/jimmunol.171.12.6891

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  108 in total

1.  NKG2D initiates caspase-mediated CD3zeta degradation and lymphocyte receptor impairments associated with human cancer and autoimmune disease.

Authors:  Nobuyoshi Hanaoka; Bana Jabri; Zhenpeng Dai; Cezary Ciszewski; Anne M Stevens; Cassian Yee; Hideki Nakakuma; Thomas Spies; Veronika Groh
Journal:  J Immunol       Date:  2010-10-06       Impact factor: 5.422

2.  Estrogen upregulates MICA/B expression in human non-small cell lung cancer through the regulation of ADAM17.

Authors:  Jing Ren; Yunzhong Nie; Mingming Lv; Sunan Shen; Ruijing Tang; Yujun Xu; Yayi Hou; Shuli Zhao; Tingting Wang
Journal:  Cell Mol Immunol       Date:  2014-11-03       Impact factor: 11.530

3.  Intact NKG2D-independent function of NK cells chronically stimulated with the NKG2D ligand Rae-1.

Authors:  Marine Champsaur; Joshua N Beilke; Kouetsu Ogasawara; Ulrich H Koszinowski; Stipan Jonjic; Lewis L Lanier
Journal:  J Immunol       Date:  2010-06-07       Impact factor: 5.422

Review 4.  Effect of NKG2D ligand expression on host immune responses.

Authors:  Marine Champsaur; Lewis L Lanier
Journal:  Immunol Rev       Date:  2010-05       Impact factor: 12.988

5.  Intranodal interaction with dendritic cells dynamically regulates surface expression of the co-stimulatory receptor CD226 protein on murine T cells.

Authors:  Sebastian Seth; Quan Qiu; Simon Danisch; Michael K Maier; Asolina Braun; Inga Ravens; Niklas Czeloth; Rebecca Hyde; Oliver Dittrich-Breiholz; Reinhold Förster; Günter Bernhardt
Journal:  J Biol Chem       Date:  2011-09-21       Impact factor: 5.157

6.  Primary B-CLL resistance to NK cell cytotoxicity can be overcome in vitro and in vivo by priming NK cells and monoclonal antibody therapy.

Authors:  Caroline Veuillen; Thérèse Aurran-Schleinitz; Rémy Castellano; Jérôme Rey; Françoise Mallet; Florence Orlanducci; Laurent Pouyet; Sylvaine Just-Landi; Diane Coso; Vadim Ivanov; Xavier Carcopino; Réda Bouabdallah; Yves Collette; Cyril Fauriat; Daniel Olive
Journal:  J Clin Immunol       Date:  2012-02-09       Impact factor: 8.317

7.  Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity.

Authors:  Masahisa Jinushi; F Stephen Hodi; Glenn Dranoff
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-05       Impact factor: 11.205

8.  Obstructing shedding of the immunostimulatory MHC class I chain-related gene B prevents tumor formation.

Authors:  Jennifer D Wu; Catherine L Atteridge; Xuanjun Wang; Tsukasa Seya; Stephen R Plymate
Journal:  Clin Cancer Res       Date:  2009-01-15       Impact factor: 12.531

Review 9.  Exploring the NK cell platform for cancer immunotherapy.

Authors:  Jacob A Myers; Jeffrey S Miller
Journal:  Nat Rev Clin Oncol       Date:  2020-09-15       Impact factor: 66.675

10.  Differential mechanisms of shedding of the glycosylphosphatidylinositol (GPI)-anchored NKG2D ligands.

Authors:  Lola Fernández-Messina; Omodele Ashiru; Philippe Boutet; Sonia Agüera-González; Jeremy N Skepper; Hugh T Reyburn; Mar Valés-Gómez
Journal:  J Biol Chem       Date:  2010-01-14       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.